Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$47.41
-3.0%		$50.91
$25.17
▼
$55.67
$7.95B0.341.37 million shs1.43 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.17
-4.8%		$109.78
$74.50
▼
$122.20
$7.34B1.92648,200 shs441,209 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$90.36
-3.5%		$98.43
$14.51
▼
$110.18
$7.95B3.03934,375 shs1.27 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$28.27
-2.6%		$24.95
$13.60
▼
$30.62
$2.01B1.15689,537 shs542,077 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
0.00%-1.90%-5.24%+12.37%+62.09%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%-2.57%+1.35%+21.34%+4.76%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%-15.15%-10.98%+22.94%+427.19%
Zymeworks Inc. stock logo
ZYME
Zymeworks
0.00%-1.40%+24.48%+12.50%+89.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$47.41
-3.0%		$50.91
$25.17
▼
$55.67
$7.95B0.341.37 million shs1.43 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.17
-4.8%		$109.78
$74.50
▼
$122.20
$7.34B1.92648,200 shs441,209 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$90.36
-3.5%		$98.43
$14.51
▼
$110.18
$7.95B3.03934,375 shs1.27 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$28.27
-2.6%		$24.95
$13.60
▼
$30.62
$2.01B1.15689,537 shs542,077 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
0.00%-1.90%-5.24%+12.37%+62.09%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%-2.57%+1.35%+21.34%+4.76%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%-15.15%-10.98%+22.94%+427.19%
Zymeworks Inc. stock logo
ZYME
Zymeworks
0.00%-1.40%+24.48%+12.50%+89.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.72
Moderate Buy$54.5615.09% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.74
Moderate Buy$141.1231.68% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.87
Moderate Buy$109.6921.39% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.73
Moderate Buy$40.0041.49% Upside

Current Analyst Ratings Breakdown

Latest ZYME, SYRE, ALKS, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$120.00
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$135.00 ➝ $127.00
8/26/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
8/26/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$130.00 ➝ $123.00
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$132.00 ➝ $121.00
8/26/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
8/26/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$32.00
8/26/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$51.00 ➝ $55.00
8/11/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$112.00 ➝ $132.00
8/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $44.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.48B5.39$1.67 per share28.32$10.78 per share4.40
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$239.92M30.61N/AN/A$1.50 per share71.45
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/A$10.86 per shareN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$37.13M54.03N/AN/A$1.13 per share25.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38124.77197.54N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$1.95N/AN/AN/AN/A-30.74%-22.23%11/3/2026 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$81.13M-$2.02N/A57.69N/A-405.31%-72.30%-37.18%11/5/2026 (Estimated)

Latest ZYME, SYRE, ALKS, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.5620-$0.62-$0.0580-$0.62$4.54 million$3.23 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
8/4/2026Q2 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7589-$0.36+$0.3989-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
18.53
18.53
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
6.32
6.32

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
Zymeworks Inc. stock logo
ZYME
Zymeworks
33.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14068.53 million64.49 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7387.94 million74.14 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46070.96 million47.18 millionN/A

Recent News About These Companies

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME
August 30 at 5:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-invests-551-million-in-zymeworks-inc-zyme-2026-08-30/
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.
August 30 at 3:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4251030-shares-in-zymeworks-inc-zyme-bought-by-blackrock-inc-2026-08-30/
FY2026 EPS Estimates for Zymeworks Boosted by HC Wainwright
August 30 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991294
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion
August 29 at 7:16 PM  |  ad-hoc-news.deA
HC Wainwright Predicts Zymeworks' Q3 Earnings (NASDAQ:ZYME)
August 29 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989183
Zymeworks (ZYME), What Is Behind The Renewed Attention?
August 28 at 5:20 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zymeworks-zyme-behind-renewed-attention-190541497.html
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright
August 28 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-fy2026-eps-estimates-for-zymeworks-raised-by-hc-wainwright-2026-08-28/
Zymeworks (NASDAQ:ZYME) Stock Price Up 11.4% on Analyst Upgrade
August 28 at 2:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30987450
Citigroup Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock
August 28 at 2:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30987461
Zymeworks (NASDAQ:ZYME) Earns Market Outperform Rating from Citizens Jmp
August 28 at 2:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30987446
Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
August 27 at 9:16 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69402828-zymeworks-inc-u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesopha-399.htm
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings
August 27 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-strong-estimate-for-zymeworks-q3-earnings-2026-08-27/
Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME
August 27 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-position-in-zymeworks-inc-zyme-2026-08-27/
SJM, ZYME stocks hit 52-week high – what’s driving the surge today?
August 26, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/sjm-zyme-stocks-hit-52-week-high-what-s-driving-the-surge-today/ar-AA2aZ03R
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980527/jazz-secures-fda-nod-for-expanded-use-of-ziihera-in-gastric-cancer?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2980527
Zymeworks (NASDAQ:ZYME) Price Target Raised to $38.00 at Citigroup
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zymeworks-nasdaq-zyme-price-target-raised-to-3800-at-citigroup-2026-08-26/
Zymeworks (NASDAQ:ZYME) Stock Price Up 11.4% After Analyst Upgrade
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zymeworks-nasdaq-zyme-stock-price-up-114-after-analyst-upgrade-2026-08-26/
Zymeworks (NASDAQ:ZYME) Given "Market Outperform" Rating at Citizens Jmp
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zymeworks-nasdaq-zyme-given-market-outperform-rating-at-citizens-jmp-2026-08-26/
HC Wainwright Increases Zymeworks (NASDAQ:ZYME) Price Target to $55.00
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-increases-zymeworks-nasdaq-zyme-price-target-to-5500-2026-08-26/
Manatuck Hill Partners LLC Acquires New Stake in Zymeworks Inc. $ZYME
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-manatuck-hill-partners-llc-acquires-new-stake-in-zymeworks-inc-zyme-2026-08-26/
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-zymeworks-inc-nasdaq-zyme-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-08-26/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Brown-Forman logo engraved on a wooden barrel, with copper distillery stills and whiskey bottles in the background.
Why Brown-Forman Rejected a 23% Premium Twice
By Chris Markoch | August 6, 2026
Red Tesla Model Y in bright showroom beside Tesla logo and Supercharger, symbolizing TSLA ahead of earnings.
What Tesla Stands to Lose If It Walks Away From China
By Sam Quirke | August 6, 2026
Semi trucks line up at a border checkpoint with U.S. and Canadian flags and a cable-stayed bridge in the background.
3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods
By Dan Schmidt | August 28, 2026
Alkermes stock logo

Alkermes NASDAQ:ALKS

$47.41 -1.49 (-3.05%)
As of 08/28/2026 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$107.17 -5.36 (-4.76%)
As of 08/28/2026 04:00 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$90.36 -3.25 (-3.47%)
As of 08/28/2026 04:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Zymeworks stock logo

Zymeworks NASDAQ:ZYME

$28.27 -0.74 (-2.55%)
As of 08/28/2026 04:00 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas